What’s Ahead for Horizon Pharma PLC After Today’s Bullish Options Activity?


 What's Ahead for Horizon Pharma PLC After Today's Bullish Options Activity?

In today’s session Horizon Pharma PLC (HZNP) registered an unusually high (221) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious HZNP increase. With 221 contracts traded and 9004 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: HZNP161118C00020000 closed last at: $0.75 or 7.1% up. About 1.55 million shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has declined 3.89% since March 14, 2016 and is downtrending. It has underperformed by 9.51% the S&P500.

Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on November, 4. They expect $0.67 EPS, up 13.56% or $0.08 from last year’s $0.59 per share. HZNP’s profit will be $107.58 million for 6.53 P/E if the $0.67 EPS becomes a reality. After $0.42 actual EPS reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts 59.52% EPS growth.

Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage

Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Horizon Pharma has been the topic of 18 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The rating was reinitiated by Morgan Stanley with “Underweight” on Thursday, December 3. The firm has “Market Perform” rating given on Friday, September 16 by Cowen & Co. The firm earned “Neutral” rating on Wednesday, January 6 by Citigroup. On Thursday, December 17 the stock rating was initiated by Goldman Sachs with “Buy”. Jefferies reinitiated the stock with “Buy” rating in Monday, November 23 report. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Tuesday, September 13. The firm has “Mkt Outperform” rating given on Wednesday, September 9 by JMP Securities. The firm has “Buy” rating by Mizuho given on Tuesday, November 10. Brean Capital downgraded Horizon Pharma PLC (NASDAQ:HZNP) on Tuesday, September 22 to “Hold” rating. The firm has “Equal-Weight” rating given on Monday, July 11 by Morgan Stanley.

According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.21, from 1 in 2016Q1. The ratio increased, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
Lakeview Cap Partners Ltd Liability Com last reported 33,348 shares in the company. Glob X Mngmt Co Ltd Liability Co accumulated 0.09% or 107,716 shares. Endurant Capital Mgmt Lp last reported 56,440 shares in the company. Broadfin Capital Limited Liability Company holds 10.99% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 6.86M shares. Finemark Natl Bank Tru holds 940 shares or 0% of its portfolio. Moreover, Deere & has 0.08% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 92,554 shares. Timessquare Cap Mngmt Limited Liability Corp has 3.86M shares for 0.42% of their US portfolio. Aqr Cap Ltd Llc last reported 86,846 shares in the company. Amalgamated Retail Bank last reported 0.02% of its portfolio in the stock. Voloridge Invest Management Ltd Liability Corp has 39,175 shares for 0.02% of their US portfolio. The Japan-based Blackrock Japan has invested 0% in Horizon Pharma PLC (NASDAQ:HZNP). Barrett Asset Mgmt Lc has 4,900 shares for 0.01% of their US portfolio. Ghost Tree Cap Ltd Llc reported 250,000 shares or 1.19% of all its holdings. Moreover, Ladenburg Thalmann Financial Services Incorporated has 0.01% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 24,416 shares. Northern, a Illinois-based fund reported 1.78 million shares.

Insider Transactions: Since June 15, 2016, the stock had 0 insider buys, and 2 insider sales for $500,280 net activity. $58,000 worth of Horizon Pharma PLC (NASDAQ:HZNP) was sold by SHERMAN JEFFREY W on Tuesday, August 2. 25,000 shares with value of $442,280 were sold by Nohria Virinder on Wednesday, June 15.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The company has a market cap of $2.81 billion. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It currently has negative earnings. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

HZNP Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.

More recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Investorplace.com which released: “Dump Horizon Pharma PLC (HZNP) Stock Now! Don’t Wait!” on October 11, 2016. Also Globenewswire.com published the news titled: “Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and …” on October 13, 2016. Moodys.com‘s news article titled: “Moody’s affirms Horizon Pharma’s B2 CFR; downgrades unsec. rating to B3” with publication date: October 13, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply